Physician

John Doster, M.D.

According to 2025 Medicare claims, John Doster, M.D. (NPI: 1982670147) practices hematology/oncology in the Greenville-Anderson-Greer, SC market, with the plurality of this provider's patient population coming from Anderson, SC. This provider's primary affiliated billing organization is ANDERSON ONCOLOGY-HEMATOLOGY CLINIC PA (NPI: 1316914161; TIN: 570749974) and primary practice location at 29621-1580.

Doster's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 847 traditional Medicare patients, billed 379,071 HCPCS/CPT codes, and received $5,969,878 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,002 prescription claims across 520 beneficiaries totaling $10,026,439 in drug costs, led by Revlimid (Lenalidomide). DME data shows 183 claims. Open Payments data shows 130 records totaling $2,813. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $4,316,098 to $10,026,439. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $22,561 to $7,277.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,159	270,650	$3,759,390
2016	1,130	320,768	$4,757,137
2017	1,389	316,002	$5,407,385
2018	1,354	529,885	$8,111,090
2019	1,101	488,962	$8,294,719
2020	994	509,351	$7,796,762
2021	926	366,072	$5,255,495
2022	910	360,290	$5,271,290
2023	885	351,823	$5,401,565
2024	847	379,071	$5,969,878

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	571	3,374	$4,316,098
2016	589	3,739	$5,775,431
2017	602	3,672	$6,866,784
2018	618	4,070	$8,603,736
2019	615	4,064	$8,877,391
2020	578	3,839	$10,275,613
2021	534	3,464	$10,694,517
2022	504	3,230	$10,435,348
2023	516	2,972	$9,717,760
2024	520	3,002	$10,026,439

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	130	431	$116,674
2016	85	314	$90,270
2017	111	251	$53,668
2018	91	238	$34,743
2019	83	184	$24,434
2020	54	113	$12,886
2021	58	187	$18,314
2022	90	218	$15,439
2023	61	127	$29,844
2024	75	183	$12,385

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	621	1,286	$93
80053	Blood test, comprehensive group of blood chemicals	689	2,428	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	759	2,912	$8
83735	Magnesium level	392	1,360	$7
83615	Lactate dehydrogenase (enzyme) level	483	1,816	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	90	2,261	$1,357,103
Ibrance	Palbociclib	61	1,708	$945,525
Lenalidomide	Lenalidomide	65	1,701	$919,857
Pomalyst	Pomalidomide	44	1,134	$867,681
Xtandi	Enzalutamide	57	1,710	$783,284

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8030	Breast prosthesis, silicone or equal, without integral adhesive	N	12	12	$4,660
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	26	37	$3,774
J8521	Capecitabine, oral, 500 mg	N	12	43	$1,661
J8700	Temozolomide, oral, 5 mg	N	N/R	21	$1,242
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	13	43	$539

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	130	$2,813	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John Doster, M.D.?

Tedicare shows public-source Medicare data for John Doster, M.D. (NPI 1982670147), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John Doster, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John Doster, M.D.?

John Doster, M.D. is linked to ANDERSON ONCOLOGY-HEMATOLOGY CLINIC PA (billing NPI 1316914161) in the available physician profile data.

Does John Doster, M.D. have Open Payments data?

John Doster, M.D. has 130 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.